📢Colorectal cancer abstracts in #ESMO24 ESMO - Eur. Oncology ✅515MO - Encorafenib + cetuximab (EC) + FOLFIRI for BRAF V600E-mutant metastatic colorectal cancer (mCRC): Updated results from the BREAKWATER safety lead-in (SLI) ✅516MO - Zanidatamab (Zani) + chemotherapy (CT) in first-line

📘Early-Onset Colorectal Cancer: From laboratory to the clinic ESMO - Eur. Oncology ✅A comprehensive review ⁉️A lot of questions remain to be answered in terms of biology, agresiveness, prognosis and screening 👉doi.org/10.1016/j.ctrv… Oncology Advance Dr. Cathy Eng Cihangir Akyol, MD Beliz Bahar Karaoğlan

Not to miss Top 10 Abstracts #ESMO24 by OncoAlert ✅👏🏻 #breast👇 Stay tuned📢

Alternative medicine therapies without standard treatments in non-metastatic patients are associated with higher risk of death about 150% ❗️ Even, in breast and colorectal cancer, it is roughly 300-400% ❗️ Yüksel Ürün ESMO - Eur. Oncology ASCO National Cancer Institute

One-question #oncpoll ❓ Would you give adjuvant chemotherapy for resected T2/3-N0 MSI-H gastric cancer ? Cancer Data etc Lizzy Smyth #cancer #oncology #MedX

⚡️Top 10 GI abstracts #ESMO24 ESMO - Eur. Oncology ✅by #OncoAlert 👇 Stay tuned 📢

The latest and greatest in #GIonc will be presented soon ESMO - Eur. Oncology #ESMO24 in #Barcelona 🇪🇸 Humbled to contribute alongside the prolific Erman Akkus and Gil Morgan, MD Make sure you follow OncoAlert🚨 for updates leading up to, through and beyond the conference.

This evening Henning Köhne gave a very nice speech and long excellent discussion on metastatic CRC treatment in Ankara. 🚨Most of the recommendations on RAS mutant status and sideness are based on retrospective subgroup analyses DKFZ Klinikum Oldenburg Enes Erul MD Onur Baş, MD Beliz Bahar Karaoğlan

Pancreatic cysts are often found incidentally on imaging tests for other indications. Imaging, symptom assessment, and laboratory tests can help distinguish benign cysts from those associated with a risk of malignant transformation. Learn more: nej.md/4g4jz5s

Among patients with leiomyosarcoma, a combination of doxorubicin and trabectedin with prolonged trabectedin maintenance therapy led to longer overall survival than doxorubicin alone (median, 33 vs. 24 months). Full LMS04 trial results: nej.md/3Xa9oDT

Our recent work: The risk of metachronous CRC in patients with EOCRC is comparable to LOCRC, but it is higher in patients with Lynch syndrome or family history of CRC. Risk of metachronous neoplasia in early-onset colorectal cancer: meta-analysis academic.oup.com/bjsopen/articl…

Top 10 lung cancer abstracts #ESMO24 ESMO - Eur. Oncology by #OncoAlert ✅

🧬Mismatch repair in pancreatic cancer JAMA Oncology ✅Although it is rare, MSI should be tested in pancreatic cancer ✅Median IO duration: 27.7 months, DCR: 80% 👉doi:10.1001/jamaoncol.2024.3651 Catherine O’Connor Emily Harrold Wungki Park, MD MS Eileen M O’Reilly #cancer #Oncology #MedX

Management of Locally Advanced Rectal Cancer: ASCO Guideline Clinical Insights 📌The article addresses the challenges clinicians may face in applying the ASCO guidelines for the management of locally advanced rectal cancer ascopubs.org/doi/10.1200/OP…

Organ preservation after neoadjuvant long-course chemoradiotherapy versus short-course radiotherapy - Annals of Oncology annalsofoncology.org/article/S0923-…

Omission of 5-FU Bolus From Multidrug Regimens 🔍Retrospective study with ~12,000 pts in GI cancer 💥Omitting 5-FU bolus had no negative impact on survival (FOLFOX, FOLFIRI, FOLFIRINOX) 💥Associated with a significant reduction in toxicity jnccn.org/view/journals/…

#ESMO24: Do not miss the latest #CancerResearch brought to you by the #ESMOAmbassadors & become part of the conversation. 📌 ow.ly/PgWM50Th6Q3

The OncoAlert 🚨Newsletter NOW OUT Covering August 30- Sept5, 2024 Register at Oncoalert360.com or oncoalert.m-pages.com/nhMpwe/oncoale… Discussing ✅TROPHY-U-01 #BladderCancer ✅DeLLphi-300🫁 SC #LungCancer ✅LITESPARK-013 #KidneyCancer ✅RADICALS-HD☢️ #ProstateCancer

Young females had the highest Average Annual Percentage Changes for pancreatic cancer in individuals younger than 35. Also shown in gastric cancer, myeloma, and colorectal malignancies. BMC Medicine pubmed.ncbi.nlm.nih.gov/39232785/

Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study out on The Lancet Oncology thelancet.com/journals/lanon… This phase 3 randomized controlled trial (CCTG HE1) aimed to